DALI PHARMACEUTICAL(SH:603963)2023-10-26 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥13,702,774.26, a decrease of 55.47% compared to the same period last year[6]. - The net profit attributable to shareholders for the same period was -¥4,606,616.41, with a year-to-date net profit of -¥15,388,969.20, indicating significant losses[6]. - The basic and diluted earnings per share for Q3 2023 were both -¥0.0210, reflecting ongoing financial challenges[7]. - Total operating revenue for the first three quarters of 2023 was CNY 73,273,235.69, a decrease from CNY 100,455,626.21 in the same period of 2022, representing a decline of approximately 27%[21]. - The net profit for Q3 2023 was -15,388,969.20 RMB, compared to -11,477,161.75 RMB in Q3 2022, indicating a decline of approximately 34.5% year-over-year[22]. - The total operating profit for Q3 2023 was -13,199,710.51 RMB, a decrease from -10,653,030.07 RMB in the same period last year[22]. - The company reported a net loss for the first three quarters of 2023, with total operating costs exceeding total operating revenue[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥464,911,796.96, down 7.66% from the previous year-end[7]. - Total assets decreased to CNY 464,911,796.96 as of September 30, 2023, down from CNY 503,486,467.80 at the end of 2022, a decline of approximately 8%[18]. - Total liabilities decreased to CNY 79,144,408.72 as of September 30, 2023, from CNY 102,330,110.36 at the end of 2022, indicating a reduction of about 23%[19]. - The company's equity attributable to shareholders decreased to CNY 385,767,388.24 as of September 30, 2023, down from CNY 401,156,357.44 at the end of 2022, a decline of approximately 4%[19]. Cash Flow - The company's cash flow from operating activities showed a year-to-date net outflow of -¥33,103,551.66, primarily due to increased raw material purchases[7]. - The company reported a net cash flow from operating activities of -33,103,551.66 RMB for the first nine months of 2023, worsening from -12,786,684.84 RMB in the same period of 2022[25]. - Cash inflow from investment activities for Q3 2023 was 312,367,207.38 RMB, significantly higher than 134,082,956.91 RMB in Q3 2022[26]. - The net cash flow from investment activities improved to 21,886,550.23 RMB in Q3 2023, compared to a negative cash flow of -114,942,472.82 RMB in Q3 2022[26]. Shareholder Information - The company reported a total of 25,432 common shareholders at the end of the reporting period[12]. - The top shareholder, Yang Junxiang, holds 51,204,200 shares, representing 23.31% of the total shares[13]. Inventory and Receivables - Accounts receivable decreased by 47.45% as the company collected some outstanding payments from customers[11]. - Inventory increased by 80.97%, indicating a strategy of maintaining adequate stock levels[11]. - Inventory increased to CNY 48,899,090.73 as of September 30, 2023, from CNY 27,020,592.03 at the end of 2022, marking an increase of about 81%[17]. - Accounts receivable decreased to CNY 3,981,715.95 as of September 30, 2023, from CNY 7,577,222.86 at the end of 2022, reflecting a decrease of about 48%[17]. Financial Adjustments and Compliance - The company implemented new accounting standards starting January 1, 2023, affecting the recognition of deferred tax assets and liabilities[27]. - The company continues to focus on compliance with new accounting standards to ensure accurate financial reporting and transparency[27]. - The adjustments made in the financial statements are part of the company's commitment to adhere to regulatory changes and improve financial accuracy[27].